Antimycotic influence of beta-cyclodextrin complexes--in vitro measurements using laser nephelometry in microtiter plates.
暂无分享,去创建一个
Peter Elsner | Eckhard Schollmeyer | Dierk Knittel | Moustafa M G Fouda | P. Elsner | U. Hipler | M. Fouda | E. Schollmeyer | D. Knittel | Uta-Christina Hipler
[1] R. Haugland,et al. Development of the FUN-1 family of fluorescent probes for vacuole labeling and viability testing of yeasts , 1997, Applied and environmental microbiology.
[2] Th. Ackermann,et al. K. A. Connors: Binding constants — the measurement of molecular complex stability, John Wiley & Sons, New York, Chichester, Brisbane, Toronto, Singapore 1987. 411 Seiten, Preis: £ 64.15 , 1987 .
[3] F. Greenwood,et al. THE PREPARATION OF I-131-LABELLED HUMAN GROWTH HORMONE OF HIGH SPECIFIC RADIOACTIVITY. , 1963, The Biochemical journal.
[4] A. Scarpellini,et al. Formation and antimycotic effect of cyclodextrin inclusion complexes of econazole and miconazole , 1993 .
[5] M. Ghannoum,et al. Evaluation of in vitro activity of ciclopirox olamine, butenafine HCl and econazole nitrate against dermatophytes, yeasts and bacteria , 2003, International journal of dermatology.
[6] T. Hoehler,et al. Ciclopirox olamine: a hydroxypyridone antifungal agent. , 1991, Clinics in dermatology.
[7] M. Brewster,et al. Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. , 1996, Journal of pharmaceutical sciences.
[8] K. A. Connors,et al. Binding Constants: The Measurement of Molecular Complex Stability , 1987 .
[9] M. Ghannoum,et al. Voriconazole (UK-109,496) inhibits the growth and alters the morphology of fluconazole-susceptible and -resistant Candida species , 1997, Antimicrobial agents and chemotherapy.
[10] Gerd Folkers,et al. Pharmacokinetic optimization in drug research , 2001 .
[11] D. Barber,et al. A logical stepwise approach to laser diffraction particle size distribution analysis methods development and validation. , 1998, Pharmaceutical development and technology.
[12] S. Costa-de-Oliveira,et al. Susceptibility to fluconazole of Candida clinical isolates determined by FUN-1 staining with flow cytometry and epifluorescence microscopy. , 2001, Journal of medical microbiology.
[13] S. López-Gómez,et al. Changes in fungal ultrastructure after short‐course ciclopiroxolamine therapy in pityriasis versicolor , 1990, Clinical and experimental dermatology.
[14] M. Ghannoum,et al. Comparison of Biofilms Formed by Candidaalbicans and Candidaparapsilosis on Bioprosthetic Surfaces , 2002, Infection and Immunity.
[15] Aditya K. Gupta,et al. Ciclopirox: an overview , 2001, International journal of dermatology.
[16] H. Korting,et al. The hydroxypyridones: a class of antimycotics of its own , 1997, Mycoses.
[17] Sanjeev Jain,et al. Itraconazole: an effective oral antifungal for onychomycosis , 2001, International journal of dermatology.
[18] P. Mura,et al. Improvement of dissolution properties and microbiological activity of miconazole and econazole by cyclodextrin complexation , 1992 .
[19] S. Ahmed,et al. Effect of cyclodextrins on the physicochemical properties and antimycotic activity of clotrimazole , 1998 .
[20] M. Másson,et al. Methods to enhance the complexation efficiency of cyclodextrins , 1999 .
[21] C. Bevan,et al. A high-throughput screening method for the determination of aqueous drug solubility using laser nephelometry in microtiter plates. , 2000, Analytical chemistry.
[22] F. Lombardo,et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings , 1997 .
[23] J. Cope. Mode of action of miconazole on Candida albicans: effect on growth, viability and K+ release. , 1980, Journal of general microbiology.